[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626754":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":30,"locations":31,"responsibleParty":51,"collaborators":56,"id":64,"slug":30,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":30,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":30,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":30,"overallStatus":34,"whyStopped":30,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"National Science and Technology Council, Taiwan","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Eicosapentaenoic Acid (EPA)","EXPERIMENTAL","Sample size (n=25). Four capsules of EPA will be administered at a dosage equal to two grams\u002Fday",[13],"Dietary Supplement: Eicosapentaenoic acid (omega-3 fatty acid)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Sample size (n=25). Four capsules of Placebo will be administered at a dosage equal to two grams\u002Fday",[19],"Dietary Supplement: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Eicosapentaenoic acid (omega-3 fatty acid)","25 participants are assigned",[9],[27],"Eicosapentaenoic Acid",{"type":22,"name":15,"description":24,"armGroupLabels":29,"otherNames":30},[15],null,[32],{"facility":33,"status":34,"city":35,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Mind Body Interface Research Center (MBI Lab & Care)","RECRUITING","Taichung","404","Taiwan",{"type":39,"coordinates":40},"Point",[41,42],120.6839,24.1469,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},"Kuan-Pin Su, MD, PhD","CONTACT","+886 (04) 2205-2121","14128","cobol@cmu.edu.tw",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":55,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Kuan-Pin","Professor","Ministry of Science and Technology, Taiwan",[57,60,63],{"name":58,"class":59},"Fondation FondaMental","OTHER",{"name":61,"class":62},"Fondation pour la Recherche Médicale (FRM)","UNKNOWN",{"name":55,"class":6},"100626754",false,"NCT07439744","NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status","Effects of 12-week n-3 PUFA Treatment (EPA) on Depressive Symptoms in Overweight\u002FObese Depressed Subjects With Low n-3 PUFA Status: Relationship With Systemic Inflammation","Inclusion Criteria:\n\n* Major depressive disorder.\n* Antidepressant drug-free.\n\nExclusion Criteria:\n\n* Schizophrenia\n* Mania\n* Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)\n* Obsessive-compulsive disorder\n* Post-traumatic stress disorder\n* Alcohol or drug abuse\u002Fdependence (except for nicotine)\n* Active suicidal ideation\n* Serious medical\u002Fneurological conditions, especially requiring corticosteroid\u002Fnon-steroidal anti-inflammatory or immunosuppressive therapies or chronic thyroid hormone replacement","ALL","18 Years","54 Years",{"count":74,"type":75},50,"ESTIMATED","INTERVENTIONAL",[78],"NA","A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g\u002Fday) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \\\u003C 8%) (81), from the Taiwanese cohort. Associations with PLA2\u002FCOX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.",[81,82],"Obese Adults","MDD","2026-02-23",{"date":85,"type":86},"2026-02-27","ACTUAL",{"date":88,"type":86},"2025-03-01",{"date":90,"type":75},"2027-12",{"name":5,"class":6},1]